Micronised progesterone: As a component of menopausal hormone therapy

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Micronised progesterone (mP) was TGA approved in 2016 for use as a progestogen in menopausal hormone therapy (MHT). It has improved bioavailability when taken orally, appears to have a more favourable breast safety profile than other progestogens, is neutral with respect to cardiovascular disease risk and does not cause adverse mood effects.

Original languageEnglish
Pages (from-to)53-55
Number of pages3
JournalMedicine Today
Volume18
Issue number1
Publication statusPublished - 1 Jan 2017

Keywords

  • Menopause
  • Progesteron therapy

Cite this